Clinical trial
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x…
NCT00206154 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00206154 |
|---|---|
| Title | A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients |
| Official title | A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease |
| Intervention type | Drug |
| Interventions | Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler |
| Enrollment | 1,500 |
| Start date | Apr 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 27, 2009 |
| Countries | Czechia, Netherlands, Poland, South Africa, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: